149 related articles for article (PubMed ID: 38195842)
1. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
[TBL] [Abstract][Full Text] [Related]
2. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
[TBL] [Abstract][Full Text] [Related]
3. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Noriega Rivera RA; Rivera YS; Tous-Beveraggi J; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499073
[TBL] [Abstract][Full Text] [Related]
5. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD.
Yang X; Sun D; Xiang H; Wang S; Huang Y; Li L; Cheng X; Liu H; Hu F; Cheng Y; Ma T; Hu M; Tian H; Tian S; Zhou Y; Zhang P; Zhang XJ; Ji YX; Hu Y; Li H; She ZG
Hepatology; 2021 Sep; 74(3):1319-1338. PubMed ID: 33894019
[TBL] [Abstract][Full Text] [Related]
7. SH3RF2 functions as an oncogene by mediating PAK4 protein stability.
Kim TW; Kang YK; Park ZY; Kim YH; Hong SW; Oh SJ; Sohn HA; Yang SJ; Jang YJ; Lee DC; Kim SY; Yoo HS; Kim E; Yeom YI; Park KC
Carcinogenesis; 2014 Mar; 35(3):624-34. PubMed ID: 24130170
[TBL] [Abstract][Full Text] [Related]
8. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
9. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
10. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
11. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling.
Li M; Hu M; Wang Y; Xia Z; Li Z; Li J; Zheng D; Zheng X; Xi M
Biochem Biophys Res Commun; 2022 Dec; 637():348-357. PubMed ID: 36423381
[TBL] [Abstract][Full Text] [Related]
12. Sh3rf2/POSHER protein promotes cell survival by ring-mediated proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty of SH3s) protein.
Wilhelm M; Kukekov NV; Schmit TL; Biagas KV; Sproul AA; Gire S; Maes ME; Xu Z; Greene LA
J Biol Chem; 2012 Jan; 287(3):2247-56. PubMed ID: 22128169
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
16. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
18. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
19. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer.
Zheng Z; Li X; Yang B; Xu Q; Zhu X; Hu L; Teng Y
Funct Integr Genomics; 2023 May; 23(2):147. PubMed ID: 37145301
[TBL] [Abstract][Full Text] [Related]
20. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
